Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma.
Case Rep Dermatol
; 12(1): 37-41, 2020.
Article
en En
| MEDLINE
| ID: mdl-32595466
ABSTRACT
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated with nivolumab. This patient achieved a complete response and continues treatment without progression signs, supporting the notion that PD-1 inhibition can induce long-term remission and is well tolerated in this type of patient.
Texto completo:
1
Colección:
01-internacional
Idioma:
En
Revista:
Case Rep Dermatol
Año:
2020
Tipo del documento:
Article
País de afiliación:
España